Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Alicja J Copik"'
Autor:
Dean A Lee, Jeremiah L Oyer, Md Faqrul Hasan, Tayler J Croom-Perez, Liza D Robles-Carrillo, Sanjana Kumar, Brendan W Andersen, Brian P Tullius, Alicja J Copik, Amanda R Campbell, Thomas A Dieffenthaller, Catherine A Cash, Jonathan E Eloriaga, Meisam Naeimi Kararoudi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background Inhibitory receptor T-cell Immunoreceptor with Ig and ITIM domains (TIGIT) expressed by Natural Killer (NK) and T cells regulates cancer immunity and has been touted as the next frontier in the development of cancer immunotherapeutics. Alt
Externí odkaz:
https://doaj.org/article/4c6550d3cfe540f09ffbff19f9a789fa
Autor:
Jeremiah L Oyer, Tayler J Croom-Perez, Liza D Robles-Carrillo, Faqrul Hasan, Sanjana Kumar, Brendan W Andersen, Javier A Rivera-Huertas, Brian P Tullius, Alicja J Copik
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e63b7da5f22e44cc8ce962614d25561c
Autor:
Alicja J Copik, Aleksander Baldys, Khanh Nguyen, Sunil Sahdeo, Hoangdung Ho, Alan Kosaka, Paul J Dietrich, Bill Fitch, John R Raymond, Anthony P D W Ford, Donald Button, Marcos E Milla
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0115701 (2015)
The α1A-AR is thought to couple predominantly to the Gαq/PLC pathway and lead to phosphoinositide hydrolysis and calcium mobilization, although certain agonists acting at this receptor have been reported to trigger activation of arachidonic acid fo
Externí odkaz:
https://doaj.org/article/f47f66804c3a42b0a43ac356b5af6f80
Autor:
Jeremiah L. Oyer, Tayler J. Croom-Perez, Thomas A. Dieffenthaller, Liza D. Robles-Carillo, Sarah B. Gitto, Deborah A. Altomare, Alicja J. Copik
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
There is a great interest in developing natural killer (NK) cells as adoptive cancer immunotherapy. For off-the-shelf approaches and to conduct multicenter clinical trials, cryopreserved NK cells are the preferred product. However, recent studies rep
Externí odkaz:
https://doaj.org/article/29e98c27f36e4709aaf856cfeec9eaf2
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Cancer immunotherapy is a highly successful and rapidly evolving treatment modality that works by augmenting the body’s own immune system. While various immune stimulation strategies such as PD-1/PD-L1 or CTLA-4 checkpoint blockade result in robust
Externí odkaz:
https://doaj.org/article/0c7a2beb4393491b8fa66ac25df1f0d2
Autor:
Md Faqrul Hasan, Tayler J. Croom-Perez, Jeremiah L. Oyer, Thomas A. Dieffenthaller, Liza D. Robles-Carrillo, Jonathan E. Eloriaga, Sanjana Kumar, Brendan W. Andersen, Alicja J. Copik
Publikováno v:
Cancers; Volume 15; Issue 10; Pages: 2712
Treatments targeting TIGIT have gained a lot of attention due to strong preclinical and early clinical results, particularly with anti-PD-(L)1 therapeutics. However, this combination has failed to meet progression-free survival endpoints in phase III
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::290eca34a9ebaaa0d3a6549c6abaebe3
Autor:
Cristina Fernandez-Valle, Maria Clara Franco, Long-Sheng Chang, Fred F. Telischi, Xue Zhong Liu, Alicja J. Copik, Julia N. Soulakova, Rulong Shen, Rahul Mittal, Denise Yan, Olena Bracho, Christine T. Dinh, Sarah S. Burns, Stephani Klingeman Plati, Marisa A. Fuse
Neurofibromatosis type 2 (NF2) is a nervous system tumor disorder caused by inactivation of the merlin tumor suppressor encoded by the NF2 gene. Bilateral vestibular schwannomas are a diagnostic hallmark of NF2. Mainstream treatment options for NF2-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e2082edda612e31101b4c151aaef003
https://doi.org/10.1158/1535-7163.c.6538786.v1
https://doi.org/10.1158/1535-7163.c.6538786.v1
Autor:
Cristina Fernandez-Valle, Maria Clara Franco, Long-Sheng Chang, Fred F. Telischi, Xue Zhong Liu, Alicja J. Copik, Julia N. Soulakova, Rulong Shen, Rahul Mittal, Denise Yan, Olena Bracho, Christine T. Dinh, Sarah S. Burns, Stephani Klingeman Plati, Marisa A. Fuse
All supplementary data - four figures and supplementary methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89058016f44c9a449071bff09a3eb168
https://doi.org/10.1158/1535-7163.22507780.v1
https://doi.org/10.1158/1535-7163.22507780.v1
Publikováno v:
OncoImmunology, Vol 7, Iss 11 (2018)
Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors. Hence, strategies that increase PD-L1 expression and tumor infiltration should ma
Externí odkaz:
https://doaj.org/article/a3ecc3d86615459fb3751b0f4a5bf805
Autor:
Deanna Deveson Lucas, Cornelia B. Landersdorfer, Jürgen B. Bulitta, Tae Hwan Kim, Dhruvitkumar S. Sutaria, Amy Wright, John D. Boyce, Arnold Louie, Alicja J. Copik, Brian T. Tsuji, Herbert P. Schweizer, Michael H. Norris, Miranda J. Wallace, Jeremiah Oyer, Carolin Werkman, Suresh Dharuman, Eric D. LoVullo, Beom Soo Shin, Yinzhi Lang, Xun Tao, Rossie H. Jimenez-Nieves, Brett A. Fleischer, Yuanyuan Jiao, Robert A. Bonomo, Venkataraman Balasubramanian, Kari B. Basso, Eunjeong Shin, Marianne Mégroz, George L. Drusano, Victoria C. Loudon-Hossler, Keisha C. Cadet, Nagakumar Bharatham, Jieqiang Zhou, Stephanie M. Reeve, Bartolomé Moyá, Nirav Shah, Alaa R. M. Sayed, Richard E. Lee
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1000-1020
Multidrug-resistant bacteria are causing a serious global health crisis. A dramatic decline in antibiotic discovery and development investment by pharmaceutical industry over the last decades has slowed the adoption of new technologies. It is imperat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d1fd44221b5ffb219142197006572e
https://doi.org/10.1002/cpt.2205
https://doi.org/10.1002/cpt.2205